Clinuvel (ASX:CUV) focuses on new product development to maintain revenue growth
Clinuvel Pharmaceuticals Limited (ASX:CUV)is a Melbourne-based specialty pharmaceutical company focusing on developing and commercialising treatments for patients diagnosed with systemic, genetic, metabolic, and life-threatening acute disorders. SCENESSE® (afamelanotide 16mg) is CUV's leading therapy, pioneering drug development for repigmentation and photoprotection. Since its launch in …
Team Kalkine |
20 Nov 2024| Read Time : 10 Mins